TSX symbol: SBS
CALGARY, Aug. 2 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular disease, today announced that its President and
CEO, Andrew Baum, is scheduled to present an overview of the Company's
achievements including an update on its insulin and Apo AI pharmaceutical
programs at the 27th Annual Canaccord Adams Global Growth Conference in
Boston. The presentation is scheduled for 5:00 PM Eastern Time on August 7,
2007, at the InterContinental Boston Hotel.
Interested parties may access the live webcast by visiting the Company's
website at www.sembiosys.com. Please connect at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may be
required to join the webcast. An audio archive of the presentation will be
available for approximately 30 days.
The Canaccord Adams Global Growth Conference is one of the oldest and
largest programs showcasing both publicly traded and privately held growth
companies. Many of the presenting public companies are covered by Canaccord
Adams' global team of equity analysts. To learn more about the conference,
contact Nadine Miller at 617.371.3842 or Nadine.Miller@CanaccordAdams.com.
About SemBioSys Genetics Inc. (www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing protein-based pharmaceuticals for metabolic and cardiovascular
diseases. The Company's lead pharmaceutical candidates, produced in the plant
host safflower, are recombinant human insulin to serve the rapidly expanding
global diabetes market and Apo AI, a next generation cardiovascular drug. In
addition to its pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing human topical, nutritional oils and
animal health markets.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.
For further information:
For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail: firstname.lastname@example.org, Internet: www.sembiosys.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: email@example.com